Literature DB >> 31773738

Nusinersen for older patients with spinal muscular atrophy: A real-world clinical setting experience.

Aravindhan Veerapandiyan1, Katy Eichinger2, Debra Guntrum2, Jennifer Kwon3, Lindsay Baker2, Erin Collins2, Emma Ciafaloni2.   

Abstract

INTRODUCTION: Clinical trials data concerning use of nusinersen in older spinal muscular atrophy (SMA) patients is lacking. We describe our center's experience in using intrathecal nusinersen for older patients in the clinical setting.
METHODS: Retrospective study.
RESULTS: Twelve patients (12-52 years old) were treated with nusinersen. Mean follow-up duration was 17.4 months (range, 4-26 months). All patients had scoliosis; 10 had spinal fusion/instrumentation. All procedures (30 cervical and 57 lumbar punctures) were technically successful. The only side effects were postprocedural headache (9%) and site pain (5.7%). Functional assessments showed stability in 6/9 patients and improvement in 3/9 patients. Subjective improvements in endurance, hand strength, and bulbar functioning critical for activities of daily living were reported in 8/12 patients. None of the patients has discontinued treatment so far. DISCUSSION: Intrathecal nusinersen can be safely delivered in older SMA patients. Available functional outcome measures are not adequate to capture meaningful subjective improvements.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  SMA; adolescents; adults; intrathecal; nusinersen; spinraza

Mesh:

Substances:

Year:  2019        PMID: 31773738     DOI: 10.1002/mus.26769

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  20 in total

Review 1.  Spinal muscular atrophy: state of the art and new therapeutic strategies.

Authors:  Sonia Messina; Maria Sframeli; Lorenzo Maggi; Adele D'Amico; Claudio Bruno; Giacomo Comi; Eugenio Mercuri
Journal:  Neurol Sci       Date:  2021-04-19       Impact factor: 3.307

2.  Nusinersen Treatment in Adults With Spinal Muscular Atrophy.

Authors:  Tina Duong; Connie Wolford; Michael P McDermott; Chelsea E Macpherson; Amy Pasternak; Allan M Glanzman; William B Martens; Elizabeth Kichula; Basil T Darras; Darryl C De Vivo; Zarazuela Zolkipli-Cunningham; Richard S Finkel; Michael Zeineh; Max Wintermark; Jacinda Sampson; Katharine A Hagerman; Sally Dunaway Young; John W Day
Journal:  Neurol Clin Pract       Date:  2021-06

Review 3.  Spinal muscular atrophy.

Authors:  Eugenio Mercuri; Charlotte J Sumner; Francesco Muntoni; Basil T Darras; Richard S Finkel
Journal:  Nat Rev Dis Primers       Date:  2022-08-04       Impact factor: 65.038

4.  Real-world Adherence to Nusinersen in Adults with Spinal Muscular Atrophy in the US: A Multi-site Chart Review Study.

Authors:  Lauren Elman; Bora Youn; Crystal M Proud; Margaret R Frey; Senda Ajroud-Driss; M Eileen McCormick; David Michelson; Michael S Cartwright; Terry Heiman-Patterson; Joseph M Choi; Aastha Chandak; Artak Khachatryan; Marta Martinez; Angela D Paradis
Journal:  J Neuromuscul Dis       Date:  2022

5.  Nusinersen in Adults with 5q Spinal Muscular Atrophy: a Systematic Review and Meta-analysis.

Authors:  Maria Gavriilaki; Maria Moschou; Vasileios Papaliagkas; Konstantinos Notas; Evangelia Chatzikyriakou; Sotirios Papagiannopoulos; Marianthi Arnaoutoglou; Vasilios K Kimiskidis
Journal:  Neurotherapeutics       Date:  2022-02-17       Impact factor: 6.088

6.  Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study.

Authors:  Astrid Pechmann; Max Behrens; Katharina Dörnbrack; Adrian Tassoni; Franziska Wenzel; Sabine Stein; Sibylle Vogt; Daniela Zöller; Günther Bernert; Tim Hagenacker; Ulrike Schara-Schmidt; Maggie C Walter; Astrid Bertsche; Katharina Vill; Matthias Baumann; Manuela Baumgartner; Isabell Cordts; Astrid Eisenkölbl; Marina Flotats-Bastardas; Johannes Friese; René Günther; Andreas Hahn; Veronka Horber; Ralf A Husain; Sabine Illsinger; Jörg Jahnel; Jessika Johannsen; Cornelia Köhler; Heike Kölbel; Monika Müller; Arpad von Moers; Annette Schwerin-Nagel; Christof Reihle; Kurt Schlachter; Gudrun Schreiber; Oliver Schwartz; Martin Smitka; Elisabeth Steiner; Regina Trollmann; Markus Weiler; Claudia Weiß; Gert Wiegand; Ekkehard Wilichowski; Andreas Ziegler; Hanns Lochmüller; Janbernd Kirschner
Journal:  Orphanet J Rare Dis       Date:  2022-10-23       Impact factor: 4.303

7.  Early experiences of nusinersen for the treatment of spinal muscular atrophy: Results from a large survey of patients and caregivers.

Authors:  Er Chen; Stacy Dixon; Rupali Naik; Josh M Noone; J Daniel Buchenberger; Sarah M Whitmire; Rosalina Mills; William Arnold
Journal:  Muscle Nerve       Date:  2020-12-19       Impact factor: 3.217

8.  Mutation analysis of 419 family and prenatal diagnosis of 339 cases of spinal muscular atrophy in China.

Authors:  Yingjie Sun; Xiangdong Kong; Zhenhua Zhao; Xuechao Zhao
Journal:  BMC Med Genet       Date:  2020-06-18       Impact factor: 2.103

9.  European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy.

Authors:  Janbernd Kirschner; Nina Butoianu; Nathalie Goemans; Jana Haberlova; Anna Kostera-Pruszczyk; Eugenio Mercuri; W Ludo van der Pol; Susana Quijano-Roy; Thomas Sejersen; Eduardo F Tizzano; Andreas Ziegler; Laurent Servais; Francesco Muntoni
Journal:  Eur J Paediatr Neurol       Date:  2020-07-09       Impact factor: 3.140

10.  Nusinersen in pediatric and adult patients with type III spinal muscular atrophy.

Authors:  Maria Carmela Pera; Giorgia Coratti; Francesca Bovis; Marika Pane; Amy Pasternak; Jacqueline Montes; Valeria A Sansone; Sally Dunaway Young; Tina Duong; Sonia Messina; Irene Mizzoni; Adele D'Amico; Matthew Civitello; Allan M Glanzman; Claudio Bruno; Francesca Salmin; Simone Morando; Roberto De Sanctis; Maria Sframeli; Laura Antonaci; Anna Lia Frongia; Annemarie Rohwer; Mariacristina Scoto; Darryl C De Vivo; Basil T Darras; John Day; William Martens; Katia A Patanella; Enrico Bertini; Francesco Muntoni; Richard Finkel; Eugenio Mercuri
Journal:  Ann Clin Transl Neurol       Date:  2021-06-24       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.